
Eli Lilly released phase 2b trial results comparing the investigational eloralintide-tirzepatide combo with tirzepatide 15 mg alone in patients with T2D and obesity.
Pediatricians have so much faith in a drug for treating neonatal hyperbilirubinemia that even though it hasn't been approved by the Food & Drug Administration yet, they are recommending its use in their just-released guidelines.






